Werner Schäfer, the founder of CIS Pharma, envisioned the synthesis of a bio-inspired polymer that would replace human tissue and could be used for site-specific drug delivery. We created exactly that, and we called it Cellophil® Smart Polymer.

Cellophil® is a platform of polymers that are based on natural l-amino-acids such as lysine, serine, threonine, proline, cysteine or tyrosine, linked to acrylics. The platform polymers show excellent biocompatibility, superior to the polymers most commonly used in the implant and drug delivery industry. In fact, biocompatibility is comparable to collagen, a natural polymer in humans. The safety of Cellophil® polymers has been demonstrated: no cytotoxic, allergic or hemolytic potential was observed. And it was also shown that the specific structures of Cellophil® Smart Polymers offer a good environment for cellular attachment.

Furthermore, Cellophil’s unique structures provide ideal contact points for the attachment and the delivery of therapeutics. Cellophil® is loaded with active compounds, from small molecules up to large protein-based drugs. The release kinetic of the immobilized therapeutics is varied using different linker chemistry.

Cellophil® Smart Polymers are compatible with a high number of polymeric building blocks. Chemical and physical characteristics of Cellophil® structures are adapted to specific criteria resulting from the targeted therapeutics, the site of delivery and release kinetics. Cellophil® can be sterilized. By the use of state-of-the-art polymerization and linking techniques, we are continuously expanding the Cellophil® platform to discover new applications in the field of nanotechnology, diagnostics and biomedicine.

CIS Pharma is currently developing a system for the solubilization and controlled release of highly hydrophobic drugs. We have also created hydrophilic coatings to improve the comfort of contact lenses. In Oncology, Cellophil® is used as a carrier for cytotoxic drugs. Here, Cellophil® Smart Carriers are used to increase the payload of antibody-drug conjugates in cancer therapies.